New hope for dialysis patients: drug targets dangerous phosphorus levels
NCT ID NCT07285291
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called TS-172 in 100 adults on hemodialysis who have high phosphorus levels. Participants will take TS-172 or a placebo alongside their usual phosphate binders. The goal is to see if TS-172 helps more patients reach safe phosphorus levels, which is important for heart and bone health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taisho Pharmaceutical Co., Ltd selected site
RECRUITINGTokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.